SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
4887 Stock Chart & Stats
¥2359.00
-¥48.50(-2.23%)
At close: 4:00 PM EST
¥2359.00
-¥48.50(-2.23%)
Day’s Range― - ―
52-Week Range¥1,650.00 - ¥2,447.00
Previous CloseN/A
Volume473.80K
Average Volume (3M)299.27K
Market Cap
¥226.64B
Enterprise Value¥341.06B
Total Cash (Recent Filing)¥46.12B
Total Debt (Recent Filing)¥122.49B
Price to Earnings (P/E)13.9
Beta0.40
Next Earnings
May 13, 2026EPS Estimate
27.73Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)42.46
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.41
Price to Sales (P/S)1.30
P/FCF Ratio33.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,640.00Price Target Upside11.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)121.3
Revenue Forecast (FY)¥203.85B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA sustained 34% TTM top-line increase indicates durable demand for the company’s generics portfolio and expanding sales scale in its core domestic market. Strong revenue momentum supports reinvestment capacity and provides a base to offset pricing or cost pressures over 2–6 months.
Positive Cash GenerationConsistent positive operating cash flow (¥20.3B TTM) and positive free cash flow (¥5.8B TTM) show the business can convert sales into cash. This underpins funding for capex, working capital and dividends, providing financial flexibility despite some FCF volatility in prior years.
Substantial Equity BaseA sizable equity cushion (¥178.8B of equity against ¥377.0B assets) and sector-manageable leverage give balance-sheet stability. This capital base supports R&D, manufacturing continuity and resilience to reimbursement or demand shifts common in generics over the medium term.
Bears Say
Margin CompressionNet margin decline from ~12.1% to ~4.9% TTM signals structural pressure on profitability, likely from pricing, mix shifts or cost increases. Persistently lower margins will reduce internal funding for growth and weaken returns, making long-term margin recovery a key risk.
Volatile Free Cash FlowWhile FCF is currently positive, its decline and historical volatility (including negative FCF in FY2023–FY2024) undermine predictability of discretionary cash. This volatility can constrain investments, increase reliance on external funding, and complicate capital allocation over multiple quarters.
Weakened Returns & Rising LeverageROE halved while debt-to-equity rose, indicating lower efficiency of capital and greater financial leverage. Reduced return on equity combined with higher leverage raises vulnerability to margin shocks and limits ability to generate attractive shareholder returns sustainably.
SAWAI GROUP HOLDINGS Co., Ltd. News
4887 FAQ
What was SAWAI GROUP HOLDINGS Co., Ltd.’s price range in the past 12 months?
SAWAI GROUP HOLDINGS Co., Ltd. lowest stock price was ¥1650.00 and its highest was ¥2447.00 in the past 12 months.
What is SAWAI GROUP HOLDINGS Co., Ltd.’s market cap?
SAWAI GROUP HOLDINGS Co., Ltd.’s market cap is ¥226.64B.
When is SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date?
SAWAI GROUP HOLDINGS Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 47 days.
How were SAWAI GROUP HOLDINGS Co., Ltd.’s earnings last quarter?
SAWAI GROUP HOLDINGS Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥42.46 earnings per share for the quarter, missing the consensus estimate of ¥58.03 by -¥15.57.
Is SAWAI GROUP HOLDINGS Co., Ltd. overvalued?
According to Wall Street analysts SAWAI GROUP HOLDINGS Co., Ltd.’s price is currently Undervalued.
Does SAWAI GROUP HOLDINGS Co., Ltd. pay dividends?
SAWAI GROUP HOLDINGS Co., Ltd. pays a Semiannually dividend of ¥28 which represents an annual dividend yield of 2.28%. See more information on SAWAI GROUP HOLDINGS Co., Ltd. dividends here
What is SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate?
SAWAI GROUP HOLDINGS Co., Ltd.’s EPS estimate is 27.73.
How many shares outstanding does SAWAI GROUP HOLDINGS Co., Ltd. have?
SAWAI GROUP HOLDINGS Co., Ltd. has 115,487,140 shares outstanding.
What happened to SAWAI GROUP HOLDINGS Co., Ltd.’s price movement after its last earnings report?
SAWAI GROUP HOLDINGS Co., Ltd. reported an EPS of ¥42.46 in its last earnings report, missing expectations of ¥58.03. Following the earnings report the stock price went down -4.582%.
Which hedge fund is a major shareholder of SAWAI GROUP HOLDINGS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
4887 Stock 12 Month Forecast
Average Price Target
¥2,640.00
▲(11.91% Upside)
Technical Analysis
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---